Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome - Wikidata - wikimedia - TriplyDB

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

http://www.wikidata.org/entity/Q28277847

about

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)The Relationship between NALP3 and Autoinflammatory Syndromes Update on Pyrin Functions and Mechanisms of Familial Mediterranean Fever Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence Working the endless puzzle of hereditary autoinflammatory disorders.Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals Why not treat human cancer with interleukin-1 blockade?Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.An update on autoinflammatory diseases Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Variable intrafamilial expressivity of the rare tumor necrosis factor-receptor associated periodic syndrome-associated mutation I170N that affects the TNFR1A cleavage site.Blocking interleukin-1 in rheumatic diseases First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation.Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives An expanding role for interleukin-1 blockade from gout to cancer.Autoinflammation: translating mechanism to therapy.The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway Targeting the inflammasome in rheumatic diseases.Therapy of autoinflammatory syndromes.Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Biological treatments: new weapons in the management of monogenic autoinflammatory disorders From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases.Monogenic autoinflammatory diseases: concept and clinical manifestations.Developments in the scientific and clinical understanding of autoinflammatory disorders Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

P2860

Q24631660-A0CBF9E4-FDA8-4D64-AE8A-131A18FD37B8 Q26749025-78EBF174-CC36-455F-A929-639DC992658C Q26749573-9CADED21-2A04-438E-9A62-3B5872F208B9 Q26799747-55695F1C-9C34-4B7D-9DF3-7E793373A9C1 Q27011650-8CC765EE-05AC-406B-A431-B43E5DEF8338 Q33357128-5146C2A7-5E8E-4132-A6F9-F0963BB670F6 Q33710807-69643163-E63C-489F-973B-9F839D940361 Q33798590-18EA33D8-A73B-465B-AF55-B4845787F6DC Q33833871-93617C16-5886-4D2B-B023-6C2A16902A19 Q34369278-3B9423FC-9747-4EAE-88A0-BC434BC976CF Q34380526-940BAC64-A3FA-410D-86FA-C71D0657D3DA Q34489840-8E514C78-FF07-4DDF-87AD-13B3450E5494 Q34632661-4608EB63-F7FA-4318-82F3-1700B75A2071 Q34781635-19BC115A-0701-4054-81A2-3DC39280368F Q34822708-0EA41633-C0C7-4638-BBC3-417681B36FB7 Q34997023-2E43C0E5-E787-494E-B44A-69E3526B1D51 Q35038000-F9106727-79B2-41BF-B49A-424CA170FDAD Q35038760-8DA5F919-F5C1-40C8-B4F2-415AD917CBFA Q35122583-0B9EBEE2-C674-4A35-8940-234C46EFAB92 Q35133812-FA2369DF-5F5A-4026-90E7-D981851E7521 Q35219001-C44C8216-AE80-4595-AE01-45DE6E143FC6 Q35558406-F2A38F52-C892-4E97-8318-82587FD4175D Q35559391-BEC4E871-6F1E-4660-A3BF-1B2F23CB495B Q35804717-36240C8B-541B-4E9B-B88F-334DE9CAC07E Q35868028-4319BC1F-3537-4988-A560-47588C142CBA Q36041225-28514299-3EF7-439F-A2B2-9829640A3F13 Q36798016-DA478FF2-CF30-49B7-9B83-79A10763C727 Q36816872-39DA368D-1793-422D-988A-901BCF6E50CD Q37077564-FF9F5016-7202-41F9-BA16-647230461C03 Q37077793-C6B7D140-8A0D-4E52-9FAB-6AC7B7F9CA1A Q37162157-BAB393B7-F355-4BF6-A35B-7BFF470195BE Q37207033-52E52861-E439-46CC-BD52-E233BEFDF2DF Q37259317-E0B2E568-E176-4883-81C4-65AE7D3172D7 Q37270409-BBD1DA44-3C92-4FC4-AB13-3769E4196C70 Q37277309-D6823A4D-A949-48DD-B860-368153D5A7AA Q37299354-D6950B1C-3C93-4F48-9EB0-E38501D0ACC9 Q37438706-66E4FBA8-71D8-483B-9869-6F95A9C3631C Q37466515-3F8F521F-572D-4594-9014-3D8575F5DDAE Q37604504-986C09A4-BACC-4DA1-9E54-296FA33625D1 Q37604702-D5757588-EC1E-4C59-AF71-AE5A77E9A9B0

P2860

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

http://www.wikidata.org/entity/Q28277847

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@ast

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@en

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@nl

type

label

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@ast

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@en

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@nl

prefLabel

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@ast

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@en

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@nl

P1433

Q28277847-563F3B43-BCCE-4A9E-B0AB-8BA562D86B36

P1476

Q28277847-3A6AE532-CABF-490D-98CB-DAABB8F71E96

P2093

Q28277847-00458BEF-1749-4C01-87F1-0A8CD6249CF3

Q28277847-68462F82-ABB1-445F-863C-9A77C4DF420C

Q28277847-8E7778CF-DD82-49D2-9D26-309D07DAEADA

Q28277847-A14ACA56-2A91-4E15-882F-EA7CF3F6FA6B

Q28277847-AFB3B5E3-4E77-4148-84D0-A33DD5CF80C8

Q28277847-D08AB967-B880-4072-834F-31884200336F

Q28277847-D55F000E-FDCC-43E4-92CC-2F0146297DE6

Q28277847-DE0EB0AF-C872-4402-80B4-56277AEFCD5F

P304

Q28277847-F6684D17-1FF9-428B-BC28-32F0160A7446

P31

Q28277847-C70AADD7-6C3C-4DDA-98AC-210CF52DA49C

P3181

Q28277847-84480E89-D670-4B36-98A7-9CB3E5EB50CD

P356

Q28277847-DE4C13F3-FE65-4E71-8886-5BCA04A0E9BE

P407

Q28277847-E1085DAD-0978-4E8D-8B37-05822BCDDC07

P433

Q28277847-11C7DBC0-28B2-4E1D-9FE2-FBD29C6C6E1D

P478

Q28277847-93AC73CB-EF52-4216-A06A-FA5251499EC0

P50

Q28277847-71185250-19AB-4F59-8A30-784DD3983EF0

Q28277847-A4AA472B-D07F-41F0-B655-69FE40FBC77C

P577

Q28277847-5BE8303B-C577-4246-8783-3008A1D6AAC0

P5875

Q28277847-C7EFB02B-9E69-4F80-8390-63C7E8F3956A

P698

Q28277847-FD54DCCB-11D5-4E69-83BE-5E1EC4445BF8

P921

Q28277847-117E88F7-CC06-46E0-B88F-D3F7BBB32D2F

P3181

P356

P1433

Arthritis and Rheumatism

P1476

Persistent efficacy of anakinr ...... r-associated periodic syndrome

@en

P2093

A Buoncompagni

http://www.w3.org/2001/XMLSchema#string

A Martini

http://www.w3.org/2001/XMLSchema#string

A Meini

http://www.w3.org/2001/XMLSchema#string

A Plebani

http://www.w3.org/2001/XMLSchema#string

M A Pelagatti

http://www.w3.org/2001/XMLSchema#string

M Gattorno

http://www.w3.org/2001/XMLSchema#string

R Barcellona

http://www.w3.org/2001/XMLSchema#string

S Federici

http://www.w3.org/2001/XMLSchema#string

P304

1516-1520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1648948

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.23475

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Giampaolo Merlini

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5413768

http://www.w3.org/2001/XMLSchema#string

P698

18438813

http://www.w3.org/2001/XMLSchema#string

P921